Aardvark Therapeutics Pauses Phase 3 HERO Trial for PWS Hunger Drug ARD-101 Over Safety Signals

Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial of ARD-101 for Prader-Willi hyperphagia after reversible cardiac signals in high-dose study. Updates expected Q2 2026.